AlzeCure gets an abstract on phase II clinical data with ACD440 for neuropathic pain accepted at pain conference

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), ) a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that an abstract on ACD440, the leading non-opioid drug candidate in the Painless platform, has been accepted for presentation at the annual pain conference to be held by the Swedish Pain Society in Uppsala, Sweden, on October 12-13.

The abstract, titled Topikal ACD440 Gel minskar smärta utlöst av temperatur-stimuli hos patienter med perifer neuropatisk smärta med sensorisk överkänslighet, will be presented at Svenskt Smärtforum 2023 by Dr. Märta Segerdahl, project leader and CMO at AlzeCure.

The presentation will include results from the completed phase II clinical trial of ACD440 in patients with peripheral neuropathic pain. This study is a double-blind, placebo-controlled, randomized crossover study aimed at evaluating the efficacy, safety and pharmacokinetics of AlzeCure's lead candidate drug in pain, ACD440.

”The study results showed a significant positive effect of ACD440 on temperature-triggered pain, which confirms our previous phase Ib study with the substance. These promising data together with the very good tolerability observed in patients further strengthen our hypotheses and bode well for the continued clinical development of ACD440,” said Dr. Segerdahl.

AlzeCure's drug candidate ACD440 is a TRPV1 antagonist for the local treatment of patients with peripheral neuropathic pain. The discovery of TRPV1 that underlies the project was awarded the Nobel Prize in Physiology or Medicine in 2021. There is thus a strong scientific basis for this biological mechanism, including its relationship to pain signaling. ACD440 completed a positive phase Ib study in 2021. It showed both very good tolerability and safety, but also a potent, long-lasting pain-relieving effect of the substance that is applied as a gel to the skin.

"ACD440 has in this clinical phase II study now shown proof-of-mechanism also in patients with significant analgesic effects on temperature-triggered pain. This in an indication area where up to 80% of the patients do not get a satisfactory effect with their current treatments. Neuropathic pain is the single largest market segment in pain management, with annual sales of over USD 11 billion, reflecting the large number of people affected," said Martin Jönsson, CEO of AlzeCure Pharma.